JavaScript is NOT enabled !

Please enable JavaScript.

Article

FT
PubMed

This record comes from PubMed

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Hanes, Jozef
Author Hanes, Jozef From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kovac, Andrej
Author Kovac, Andrej From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kvartsberg, Hlin
Author Kvartsberg, Hlin From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kontsekova, Eva
Author Kontsekova, Eva From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Fialova, Lubica
Author Fialova, Lubica From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Katina, Stanislav
Author Katina, Stanislav ORCID From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Kovacech, Branislav
Author Kovacech, Branislav From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Stevens, Eva
Author Stevens, Eva From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Hort, Jakub
Author Hort, Jakub From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Vyhnalek, Martin
Author Vyhnalek, Martin From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Boonkamp, Lynn
Author Boonkamp, Lynn From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Novak, Michal
Author Novak, Michal From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Zetterberg, Henrik
Author Zetterberg, Henrik From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Hansson, Oskar
Author Hansson, Oskar From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Scheltens, Philip
Author Scheltens, Philip ORCID From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Blennow, Kaj
Author Blennow, Kaj From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Teunissen, Charlotte E
Author Teunissen, Charlotte E From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands
Zilka, Norbert
Author Zilka, Norbert From the AXON Neuroscience R&D Services SE (J. Hanes, A.K., E.K., L.F., B.K., E.S., N.Z.), Bratislava, Slovakia; Department of Psychiatry and Neurochemistry (H.K., H.Z., K.B.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal; Clinical Neurochemistry Laboratory (H.K., H.Z., K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; AXON Neuroscience CRM Services SE (S.K.), Bratislava, Slovakia; International Clinical Research Centre (J. Hort, M.V.), St. Anne's University Hospital Brno; Memory Clinic, Department of Neurology (J. Hort, M.V.), Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic; Department of Clinical Chemistry, Neurochemistry Laboratory (L.B., C.E.T.), Amsterdam Neuroscience, VU University Medical Center Amsterdam, the Netherlands; Axon Neuroscience SE (M.N.), Larnaca, Cyprus; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology, Queen Square, London; UK Dementia Research Institute at UCL (H.Z.), London; Clinical Memory Research Unit (O.H.), Department of Clinical Sciences Malmö, Lund University; Memory Clinic (O.H.), Skåne University Hospital, Malmö, Sweden; and Department of Neurology, Alzheimer Center (P.S.), Amsterdam Neuroscience, the Netherlands. zilka@axon-neuroscience.eu

Neurology. 2020 Dec 01 ; 95 (22) : e3026-e3035. [epub] 20200924

ISSN 1526-632X | 0028-3878
Source

Language English Country United States Media print-electronic

Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link https://www.medvik.cz/link/pmid32973122

Online Full text

PubMed 32973122
PubMed Central PMC7734919
DOI 10.1212/wnl.0000000000010814
PII: WNL.0000000000010814
Knihovny.cz E-resources

OBJECTIVE: To investigate whether tau phosphorylated at Thr217 (p-tau T217) assay in CSF can distinguish patients with Alzheimer disease (AD) from patients with other dementias and healthy controls. METHODS: We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF. There was a total of 190 participants from 3 cohorts with AD (n = 77) and other neurodegenerative diseases (n = 69) as well as healthy participants (n = 44). RESULTS: The p-tau T217 assay (cutoff 242 pg/mL) identified patients with AD with accuracy of 90%, with 78% positive predictive value (PPV), 97% negative predictive value (NPV), 93% sensitivity, and 88% specificity, compared favorably with p-tau T181 ELISA (52 pg/mL), showing 78% accuracy, 58% PPV, 98% NPV, 71% specificity, and 97% sensitivity. The assay distinguished patients with AD from age-matched healthy controls (cutoff 163 pg/mL, 98% sensitivity, 93% specificity), similarly to p-tau T181 ELISA (cutoff 60 pg/mL, 96% sensitivity, 86% specificity). In patients with AD, we found a strong correlation between p-tau T217 and p-tau T181, total tau and β-amyloid 40, but not β-amyloid 42. CONCLUSIONS: This study demonstrates that p-tau T217 displayed better diagnostic accuracy than p-tau T181. The data suggest that the new p-tau T217 assay has potential as an AD diagnostic test in clinical evaluation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that a CSF immunoassay for p-tau T217 distinguishes patients with AD from patients with other dementias and healthy controls.

From the AXON Neuroscience R and D Services SE Amsterdam Neuroscience the Netherlands

See more in PubMed

Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med 2018;284:643–663. PubMed

Blennow K. CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment. Expert Rev Mol Diagn 2005;5:661–672. PubMed

Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–613. PubMed

Molinuevo JL, Ayton S, Batrla R, et al. . Current state of Alzheimer's fluid biomarkers. Acta Neuropathol 2018;136:821–853. PubMed PMC

Jack CR Jr, Bennett DA, Blennow K, et al. . NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement 2018;14:535–562. PubMed PMC

Barthélemy NR, Bateman RJ, Marin P, et al. . Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-β pathology. bioRxiv 2017.

Barthélemy NR, Mallipeddi N, Moiseyev P, Sato C, Bateman RJ. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. Extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer's disease. Front Aging Neurosci 2019;11. PubMed PMC

Sato C, Barthélemy NR, Mawuenyega KG, et al. . Tau kinetics in neurons and the human central nervous system. Neuron 2018;97:1284–1298. PubMed PMC

Kontsekova E, Novak M, Kontsek P, Borecky L, Lesso J. The effect of postfusion cell density on establishment of hybridomas. Folia Biol 1988;34:18–22. PubMed

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, et al. . A practical guide to immunoassay method validation. Front Neurol 2015;6. PubMed PMC

van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis 2018;62:1091–1111. PubMed PMC

McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–269. PubMed PMC

Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–1014. PubMed PMC

Höglinger GU, Respondek G, Stamelou M, et al. . Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 2017;32:853–864. PubMed PMC

Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503. PubMed PMC

Vanderstichele H, Bibl M, Engelborghs S, et al. . Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012;8:65–73. PubMed

Engelborghs S, Niemantsverdriet E, Struyfs H, et al. . Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimers Dement 2017;8:111–126. PubMed PMC

Pepe MS, Pepe PBMS. The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford: Oxford University Press; 2003.

DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845. PubMed

Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando, FL: Academic Press; 1986.

Gayen AK. The frequency distribution of the product-moment correlation coefficient in random samples of any size drawn from non-normal universes. Biometrika 1951;38:219–247. PubMed

Alafuzoff I, Arzberger T, Al-Sarraj S, et al. . Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol 2008;18:484–496. PubMed PMC

Janelidze S, Stomrud E, Smith R, et al. . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun 2020;11. PubMed PMC

Barthelemy NR, Hirtz C, Lehmann S, et al. . Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. Alzheimers Res Ther Alzheimer's Res Ther 2020;12. PubMed PMC

Lippa CF, Ozawa K, Mann DMA, et al. . Deposition of β-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease. Arch Neurol 1999;56:1111–1118. PubMed

Cirrito JR, Kang J-E, Lee J, et al. . Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008;58:42–51. PubMed PMC

Yamada K, Holth JK, Liao F, et al. . Neuronal activity regulates extracellular tau in vivo. J Exp Med 2014;211:387–393. PubMed PMC

Newest 20 citations...

See more in
Medvik | PubMed

Are We Estimating the Mean and Variance Correctly in the Presence of Observations Outside of Measurable Range?

Pharmacology research & perspectives. 2025 Feb ; 13 (1) : e70048.

Pharmacol Res Perspect
ISSN 2052-1707
Source

Separation of Isomeric Tau Phosphopeptides from Alzheimer's Disease Brain by Cyclic Ion Mobility Mass Spectrometry

Journal of the American Society for Mass Spectrometry. 2023 Mar 01 ; 34 (3) : 394-400. [epub] 20230127

J Am Soc Mass Spectrom
ISSN 1879-1123 | 1044-0305
Source

Borrow
RIS

Find record

In BMC

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias

Find record

Citation metrics

Archiving options